Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Feng T, Luo X, Cao W, Man R, Feng X, Song Y. Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors. Comput Intell Neurosci 2022;2022:5655009. [PMID: 35586106 DOI: 10.1155/2022/5655009] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 04/13/2022] [Accepted: 04/19/2022] [Indexed: 01/06/2023]

For:	Feng T, Luo X, Cao W, Man R, Feng X, Song Y. Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors. Comput Intell Neurosci 2022;2022:5655009. [PMID: 35586106 DOI: 10.1155/2022/5655009] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/22/2022] [Revised: 04/13/2022] [Accepted: 04/19/2022] [Indexed: 01/06/2023]

Number	Cited by Other Article(s)
1	Retracted: Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors. COMPUTATIONAL INTELLIGENCE AND NEUROSCIENCE 2022;2022:9854614. [PMID: 36601276 PMCID: PMC9807300 DOI: 10.1155/2022/9854614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Accepted: 11/23/2022] [Indexed: 12/27/2022] Abstract [This retracts the article DOI: 10.1155/2022/5655009.]. Collapse Key Words Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Retracted: Effects of CIK Cell Therapy Combined with Camrelizumab on the Quality of Life in Patients with Nasopharyngeal Carcinoma and Analysis of Prognostic Factors. COMPUTATIONAL INTELLIGENCE AND NEUROSCIENCE 2022;2022:9854614. [PMID: 36601276 PMCID: PMC9807300 DOI: 10.1155/2022/9854614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Accepted: 11/23/2022] [Indexed: 12/27/2022]